Understanding The Role Of MAIT Cells In Health And Disease
Funder
National Health and Medical Research Council
Funding Amount
$547,593.00
Summary
A specialised set of T lymphocytes called Mucosal Associated Invariant T (MAIT) cells protect us from bacteria and yeast at mucosal sites where the body's immune defences are most easily breached, e.g. gut, oral cavity, airways & reproductive tract. This study investigates the role of MAIT cells in health and in diseases like inflammatory bowel disease, peptic ulceration, periodontitis and tuberculosis. Controlling MAIT cells could help in treating these conditions.
Cell Surface Mucins In Gastrointestinal Infection, Inflammation And Cancer Development
Funder
National Health and Medical Research Council
Funding Amount
$469,627.00
Summary
Cell surface mucins are protective molecules that line all the wet surface of the body, including the gastrointestinal tract. Our research has uncovered that mucins regulate cell growth and cell death. Inappropriate control by the mucins, could lead to chronic inflammation and formation of cancers. We will test how important these molecules are in the development of cancers in the intestine, and further explore the mechanism of action.
Hypoxic Regulation Of Integrin Beta1 During Mucosal Wound Healing
Funder
National Health and Medical Research Council
Funding Amount
$318,104.00
Summary
Very little is currently known about how healing is initiated in the gut. Further understanding may allow us to improve the treatment of IBD wounding and allow new therapies to control the disease. Our work examines the role of an adhesion protein, ?1 integrin, important in the repair of intestinal wounds. Understanding the mechanisms of how ?1 integrin is involved in wound healing may allow the rational design of therapies to aid or accelerate wound healing in inflammatory disease.
Gastrokine 2 Promotes Gastric Homeostasis And Inhibits Bacterial Pathology
Funder
National Health and Medical Research Council
Funding Amount
$621,335.00
Summary
Gastrokine 2 is a small regulatory protein secreted by the stomach lining. Its function is unknown but data from our lab suggests that it may be important in maintaining stomach integrity. This project will investigate how gastrokine 2 maintains stomach function, how this can be compromised when bacterial infection is ongoing, and how we might be able to turn up gastrokine 2 expression to prevent inflammation and precancerous changes in the stomach lining.
Interferon Epsilon, A Key Cytokine In The Pathophysiology Of The Female Reproductive Tract Mucosa
Funder
National Health and Medical Research Council
Funding Amount
$793,303.00
Summary
The female reproductive tract is a complex environment, which permits pregnancy but protects against infections, all under the influence of hormones and the resident microbial flora. We have discovered a novel protein called interferon epsilon that acts on cells in the female reproductive tract to regulate protection against infections. We aim to discover how this new protein works and will determine its therapeutic potential in infections and inflammatory diseases affecting women's health.
A Novel Therapeutic Target For Preventing Helicobacter Pylori-associated Diseases
Funder
National Health and Medical Research Council
Funding Amount
$750,336.00
Summary
Gastric cancer mainly results from chronic inflammation (gastritis) caused by the stomach-dwelling bacterium, Helicobacter pylori. We have identified a potassium channel which our data suggest could be a new therapeutic target for protecting against gastric cancer caused by H. pylori infection. This project will test the role of this channel in H. pylori gastritis and see whether drugs that target this channel can protect mice against H. pylori-associated disease.
Epithelial Metabolism As A Mediator Of Host-microbiome Interactions In Inflammatory Bowel Disease
Funder
National Health and Medical Research Council
Funding Amount
$833,648.00
Summary
This project examines how the changes in the intestinal environment during inflammation influences the behaviour of bacteria within the micobiome and whether those changes can be counteracted to sustain a healthy microbiome, even during episodes of disease. This work uses cell and animal models to examine how inflammation changes the intestinal nutrients that the microbiome requires to maintain its community and whether supplementing the microbiome with these nutrients can prevent disease.
A Multi-protein Vaccine Targeting The Oral Pathogens Associated With Chronic Periodontitis
Funder
National Health and Medical Research Council
Funding Amount
$717,692.00
Summary
Periodontitis is a chronic inflammatory disease associated with specific bacteria leading to the destruction of the toothÍs supporting tissues and ultimately tooth loss and is a major public health problem in all societies. Our research is focused on designing a vaccine that targets the major bacteria associated with periodontitis. We aim to produce a triple antigen vaccine and investigate the applicability of a vaccine administered under the tongue as an alternative to needle injections.
Towards Better Treatments For Acral Melanoma Through Functional Genomics
Funder
National Health and Medical Research Council
Funding Amount
$1,456,823.00
Summary
Acral melanoma is an uncommon melanoma subtype with bad prognosis that has been poorly characterised at the molecular level. The project will conduct comprehensive analysis of acral melanoma at the DNA, RNA and protein levels. Through subsequent functional follow-up studies of key drivers of this cancer type we will identify novel drug targets to treat this disease.
Prevention Of Asthma In Young Children Via Immunostimulation
Funder
National Health and Medical Research Council
Funding Amount
$679,683.00
Summary
Persistent asthma is a major problem for Australia yet none of the current therapies do more that control the condition. The long-term solution is to prevent asthma from progressing to the persistent form. The major risk factors are: family history, early allergy and recurrent severe lower respiratory infections (sLRI) in the early life. We will conduct a randomized clinical trial to prevent sLRI using a novel bacterial-derived immunostimulant in infants at high risk of developing asthma.